NANO MED

Company Snapshot

Founded: 2020

Entity Type: Private

Region: Israel

Headquarter: Israel

Key Geographics: Middle East

Corporate Address: 6 Weizmann Street Tel-Aviv 64239 Israel Tel. +972-3-697118 www.nano24med.com

Company Overview

Nano Med is a clinical-stage company developing the new generation of steroids; CD24-enriched exosomes, as immunomodulators to treat hyper-activation of the immune system.

NANO MED In Reports

Exosome Diagnostics, Therapeutics and Research Tools: Global Markets

BCC Research Market Report provides an overview of Exosome Diagnostics and Therapeutics Market scope of the study is global. Current and projected market forecasts during the forecast period (2023 to 2028).

View All Reports

NANO MED In News

Immuno Nano Med wins $15,000 top prize at UI JPEC Innovation Challenge - Corridor Business Journal

Corridor Business Journal - Nov 20, 2025

Tissue nanotransfection and cellular reprogramming in regenerative medicine and antimicrobial dynamics - Frontiers

Frontiers - Jun 17, 2025

Nano Healthcare Technology for Medical Equipment Market Size to Hit USD 14.63 Bn by 2034 - Precedence Research

Precedence Research - Jun 25, 2025

UH Mānoa brings world’s top nano scientists to Hawaiʻi - University of Hawaii System

University of Hawaii System - Dec 10, 2024

Read All News

Company's Business Segments

Immunomodulators : The company provides advanced immunomodulators using nanotechnology, including CD24-enriched exosomes, a steroid alternative for cytokine storm therapy.

Applications/End User Industries

Healthcare